{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:04:15Z","timestamp":1790805855765,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1839,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Ionis Pharmaceuticals, Inc., Carlsbad, CA"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Amyloidogenic transthyretin (ATTR) amyloidosis is a fatal disease characterized by progressive cardiomyopathy and\/or polyneuropathy. AKCEA-TTR-LRx (ION-682884) is a ligand-conjugated antisense drug designed for receptor-mediated uptake by hepatocytes, the primary source of circulating transthyretin (TTR). Enhanced delivery of the antisense pharmacophore is expected to increase drug potency and support lower, less frequent dosing in treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>AKCEA-TTR-LRx demonstrated an approximate 50-fold and 30-fold increase in potency compared with the unconjugated antisense drug, inotersen, in human hepatocyte cell culture and mice expressing a mutated human genomic TTR sequence, respectively. This increase in potency was supported by a preferential distribution of AKCEA-TTR-LRx to liver hepatocytes in the transgenic hTTR mouse model. A randomized, placebo-controlled, phase 1 study was conducted to evaluate AKCEA-TTR-LRx in healthy volunteers (ClinicalTrials.gov: NCT03728634). Eligible participants were assigned to one of three multiple-dose cohorts (45, 60, and 90 mg) or a single-dose cohort (120 mg), and then randomized 10:2 (active : placebo) to receive a total of 4 SC doses (Day 1, 29, 57, and 85) in the multiple-dose cohorts or 1 SC dose in the single-dose cohort. The primary endpoint was safety and tolerability; pharmacokinetics and pharmacodynamics were secondary endpoints. All randomized participants completed treatment. No serious adverse events were reported. In the multiple-dose cohorts, AKCEA-TTR-LRx reduced TTR levels from baseline to 2 weeks after the last dose of 45, 60, or 90 mg by a mean (SD) of \u221285.7% (8.0), \u221290.5% (7.4), and \u221293.8% (3.4), compared with \u22125.9% (14.0) for pooled placebo (P &amp;lt; 0.001). A maximum mean (SD) reduction in TTR levels of \u221286.3% (6.5) from baseline was achieved after a single dose of 120 mg AKCEA-TTR-LRx.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest an improved safety and tolerability profile with the increase in potency achieved by productive receptor-mediated uptake of AKCEA-TTR-LRx by hepatocytes and supports further development of AKCEA-TTR-LRx for the treatment of ATTR polyneuropathy and cardiomyopathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13154","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T03:35:47Z","timestamp":1607312147000},"page":"652-661","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Ligand Conjugated Antisense Oligonucleotide for the Treatment of Transthyretin Amyloidosis: Preclinical and Phase 1 Data"],"prefix":"10.1093","volume":"8","author":[{"given":"Nicholas J.","family":"Viney","sequence":"first","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA, 92010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuling","family":"Guo","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA, 92010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jung","family":"Tai","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA, 92010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda F.","family":"Baker","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA, 92010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Aghajan","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA, 92010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiangtung W.","family":"Jung","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA, 92010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie Z.","family":"Yu","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA, 92010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"Booten","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA, 92010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Murray","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA, 92010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Machemer","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA, 92010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Burel","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA, 92010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Murray","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA, 92010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Buchele","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA, 92010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA, 92010 ,","place":["USA"]},{"name":"University of California San Diego , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Schneider","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA, 92010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Geary","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA, 92010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrill D.","family":"Benson","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett P.","family":"Monia","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA, 92010 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"key":"2026012114041671100_ehf213154-bib-0001","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"2026012114041671100_ehf213154-bib-0002","first-page":"396","article-title":"Amyloidosis as a systemic disease in context","volume":"36","author":"Cuddy","year":"2020","journal-title":"Can J Cardiol"},{"key":"2026012114041671100_ehf213154-bib-0003","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"2026012114041671100_ehf213154-bib-0004","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012114041671100_ehf213154-bib-0005","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026012114041671100_ehf213154-bib-0006","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026012114041671100_ehf213154-bib-0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"2026012114041671100_ehf213154-bib-0008","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu Rev Med"},{"key":"2026012114041671100_ehf213154-bib-0009","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab"},{"key":"2026012114041671100_ehf213154-bib-0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012114041671100_ehf213154-bib-0011","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012114041671100_ehf213154-bib-0012","doi-asserted-by":"crossref","first-page":"28270","DOI":"10.1074\/jbc.274.40.28270","article-title":"Properties of cloned and expressed human RNase H1","volume":"274","author":"Wu","year":"1999","journal-title":"J Biol Chem"},{"key":"2026012114041671100_ehf213154-bib-0013","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/9304","article-title":"Crystal structure and improved antisense properties of 2\u2032-O-(2-methoxyethyl)-RNA","volume":"6","author":"Teplova","year":"1999","journal-title":"Nat Struct Biol"},{"key":"2026012114041671100_ehf213154-bib-0014","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/17425250902877680","article-title":"Antisense oligonucleotide pharmacokinetics and metabolism","volume":"5","author":"Geary","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026012114041671100_ehf213154-bib-0015","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1021\/acs.accounts.9b00368","article-title":"Lipid nanoparticle technology for clinical translation of siRNA therapeutics","volume":"52","author":"Kulkarni","year":"2019","journal-title":"Acc Chem Res"},{"key":"2026012114041671100_ehf213154-bib-0016","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2026012114041671100_ehf213154-bib-0017","doi-asserted-by":"crossref","first-page":"12388","DOI":"10.1093\/nar\/gkx960","article-title":"Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes","volume":"45","author":"Tanowitz","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2026012114041671100_ehf213154-bib-0018","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2016.31","article-title":"Elucidation of the biotransformation pathways of a Galnac3-conjugated antisense oligonucleotide in rats and monkeys","volume":"5","author":"Shemesh","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026012114041671100_ehf213154-bib-0019","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1089\/nat.2018.0753","article-title":"Integrated Assessment of the clinical performance of GalNAc3-conjugated 2\u2032-O-methoxyethyl chimeric antisense oligonucleotides: I. Human Volunteer Experience","volume":"29","author":"Crooke","year":"2019","journal-title":"Nucleic Acid Ther"},{"key":"2026012114041671100_ehf213154-bib-0020","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/17425255.2019.1621838","article-title":"Pharmacokinetics and clinical pharmacology considerations of GalNAc3-conjugated antisense oligonucleotides","volume":"15","author":"Wang","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026012114041671100_ehf213154-bib-0021","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"2026012114041671100_ehf213154-bib-0022","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012114041671100_ehf213154-bib-0023","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012114041671100_ehf213154-bib-0024","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012114041671100_ehf213154-bib-0025","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","article-title":"Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides","volume":"23","author":"Ackermann","year":"2016","journal-title":"Amyloid"},{"key":"2026012114041671100_ehf213154-bib-0026","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1021\/acs.jmedchem.5b01948","article-title":"Comprehensive structure-activity relationship of triantennary N-acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes","volume":"59","author":"Prakash","year":"2016","journal-title":"J Med Chem"},{"key":"2026012114041671100_ehf213154-bib-0027","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/154545704322988021","article-title":"Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA)","volume":"14","author":"Vollmer","year":"2004","journal-title":"Oligonucleotides"},{"key":"2026012114041671100_ehf213154-bib-0028","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/abio.2002.5576","article-title":"Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma","volume":"304","author":"Yu","year":"2002","journal-title":"Anal Biochem"},{"key":"2026012114041671100_ehf213154-bib-0029","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2016.26","article-title":"Disposition and pharmacology of a GalNAc3-conjugated ASO targeting human lipoprotein (a) in mice","volume":"5","author":"Yu","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026012114041671100_ehf213154-bib-0030","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/nat.2016.0623","article-title":"Disposition and pharmacokinetics of a GalNAc3-conjugated antisense oligonucleotide targeting human lipoprotein (a) in monkeys","volume":"26","author":"Yu","year":"2016","journal-title":"Nucleic Acid Ther"},{"key":"2026012114041671100_ehf213154-bib-0031","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ymthe.2016.10.019","article-title":"Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate","volume":"25","author":"Zimmermann","year":"2017","journal-title":"Mol Ther"},{"key":"2026012114041671100_ehf213154-bib-0032","volume-title":"ENDEAVOUR: Phase 3 multicenter study of revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC)"},{"key":"2026012114041671100_ehf213154-bib-0033","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nbt1216-1213","article-title":"Alnylam terminates revusiran program, stock plunges","volume":"34","author":"Garber","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2026012114041671100_ehf213154-bib-0034","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026012114041671100_ehf213154-bib-0035","volume-title":"Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases patent United States patent 10,683,501","author":"Zimmermann","year":"2020"},{"key":"2026012114041671100_ehf213154-bib-0036","doi-asserted-by":"crossref","first-page":"10969","DOI":"10.1093\/nar\/gkx818","article-title":"Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates","volume":"45","author":"Nair","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2026012114041671100_ehf213154-bib-0037","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity","volume":"9","author":"Janas","year":"2018","journal-title":"Nat Commun"},{"key":"2026012114041671100_ehf213154-bib-0038","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1093\/nar\/gkz140","article-title":"Safety evaluation of 2\u2032-deoxy-2\u2032-fluoro nucleotides in GalNAc-siRNA conjugates","volume":"47","author":"Janas","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2026012114041671100_ehf213154-bib-0039","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026012114041671100_ehf213154-bib-0040","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012114041671100_ehf213154-bib-0041","volume-title":"Tegsedi [prescribing information]","year":"2019"},{"key":"2026012114041671100_ehf213154-bib-0042","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1089\/nat.2019.0829","article-title":"Underlying immune disorder may predispose some transthyretin amyloidosis subjects to inotersen-mediated thrombocytopenia","volume":"30","author":"Narayanan","year":"2020","journal-title":"Nucleic Acid Ther"},{"key":"2026012114041671100_ehf213154-bib-0043","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1517\/17425255.2013.737320","article-title":"Clinical pharmacokinetics of second generation antisense oligonucleotides","volume":"9","author":"Yu","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026012114041671100_ehf213154-bib-0044","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.omtn.2017.08.012","article-title":"Assessment of the drug interaction potential of unconjugated and GalNAc3-conjugated 2\u2032-MOE-ASOs","volume":"9","author":"Shemesh","year":"2017","journal-title":"Mol Ther Nucleic Acids"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13154","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13154","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/1\/652\/65798886\/eschf_8_1_652.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/1\/652\/65798886\/eschf_8_1_652.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:04:46Z","timestamp":1769022286000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/1\/652\/8369322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,7]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,7]]},"published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13154","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2]]},"published":{"date-parts":[[2020,12,7]]},"assertion":[{"value":"2020-08-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}